Some price data may be temporarily unavailable.
The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
Dynavax Technologies Corp. operates as a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel vaccines and immuno-oncology therapeutics. Its product includes HEPLISAV-B, which prevents infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older. The company was founded by Lawrence M. Lichtenstein, Dennis A. Carson, and Eyal Raz on August 29, 1996 and is headquartered in Emeryville, CA.
This vaccine-focused biotech reported a significant insider sale as it advances its hepatitis B franchise and global partnerships.
A healthcare titan wants to buy the biotech's vaccines.
No podcast episodes available.
DVAX earnings call for the period ending December 31, 2024.
DVAX earnings call for the period ending September 30, 2024.
DVAX earnings call for the period ending June 30, 2024.
DVAX earnings call for the period ending March 31, 2024.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.